Peripheral Neuropathy (Sensory Neuropathy) Global Clinical Trials Review, H1, 2018

2018-05-18
Price :
Published : May-2018
No. of Pages : 168

Peripheral Neuropathy (Sensory Neuropathy) Global Clinical Trials Review, H1, 2018

Summary

GlobalData’s clinical trial report, “Peripheral Neuropathy (Sensory Neuropathy) Global Clinical Trials Review, H1, 2018” provides an overview of Peripheral Neuropathy (Sensory Neuropathy) clinical trials scenario. This report provides top line data relating to the clinical trials on Peripheral Neuropathy (Sensory Neuropathy). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– The report provides a snapshot of the global clinical trials landscape
– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
– The Report provides enrollment trends for the past five years
– Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

– Assists in formulating key business strategies with regards to investment
– Helps in identifying prominent locations for conducting clinical trials which saves time and cost
– Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
– Supports understanding of trials count and enrollment trends by country in global therapeutics market
– Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
– Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Filed in: Biotechnology
Publisher : GlobalData
More Reports
Title Price Buy Now

Biotechnology – Thematic Research

Biotechnology - Thematic Research Summary At its core, biotechnology is harnessing biological and molecular systems to develop products and processes. This report focuses on the most important and fastest growing areas of biotechnology which are its application to health and medicine. It is divided into three areas: agricultural biotechnology, which includes development of genetically modified crops; industrial biotechnology, which includes production of chemicals, paper and textiles; and medical biotechnology which includes the themes covered in this report such as biosimilars and the microbiome. The thematic report also predicts that companies which make the most effective use of the modern data tools are going to be successful while, in the long run, big pharma could be threatened b......
$1950

Amyotrophic Lateral Sclerosis: Opportunity Analysis and Forecast to 2027

Amyotrophic Lateral Sclerosis: Opportunity Analysis and Forecast to 2027 Summary Amyotrophic Lateral Sclerosis (ALS) is a motor neuron degenerative disease which affects both upper motor neurons (UMN) and lower motor neurons (LMN). It is a progressive disease, with patients becoming increasingly dependent on carers and physicians as time from onset increases, and ultimately, it is fatal. ALS can be split into two origins, hereditary - which is known as FALS (Familial ALS) or idiopathic - known as SALS (sporadic ALS). Currently there are only two drugs on the market that are approved for the treatment of ALS; Sanofi's Rilutek (riluzole) and Mitsubishi Tanabe Pharma's Radicava (edaravone). The drugs were special cases in terms of FDA approval, they did not meet the normal regulatory requi......
$10995

Multiple Sclerosis: Competitive Landscape to 2026

Multiple Sclerosis: Competitive Landscape to 2026 Summary Multiple Sclerosis (MS) is primarily considered an inflammatory demyelinating disorder of the CNS due to a dysfunctional immune system, leading to neurological disability1. The etiology of MS remains unknown; however, it is widely regarded as a complex interaction of genetic susceptibility, dysfunction of the immune system, and environmental factors. This report provides an assessment of the pipeline, clinical, and commercial landscape of MS. Overall, GlobalData expects that new drug approvals will expand the treatment options and drive MS market growth over the next decade (2016-2026). Scope This report combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the ......
$3495

Gene Therapy in CVMD

Gene Therapy in CVMD Summary Gene therapies have been a point of discussion during the last several years as a potential curative option for a variety of disease indications. While mainly still in preclinical stages, gene therapy aims to treat or alleviate a disease by genetically modifying the cells of a patient. This report focuses on gene therapies in development across the 8MM for cardiovascular and metabolic disorders, including coronary artery disease, critical limb ischemia, diabetic foot ulcers, and Pompe Disease. In addition, this report provides an assessment of the pipeline, clinical, and commercial landscape of gene therapies in CVMD supplemented with a variety of KOL and payer perspectives. Scope This report combines KOL and Payer insights along with data from the ......
$7995

Panic Disorders Global Clinical Trials Review, H1, 2018

Panic Disorders Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Panic Disorders Global Clinical Trials Review, H1, 2018" provides an overview of Panic Disorders clinical trials scenario. This report provides top line data relating to the clinical trials on Panic Disorders. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. ......
$2500

The Biopharmaceutical Industry in 2017: Highlights by Therapeutic Area

The Biopharmaceutical Industry in 2017: Highlights by Therapeutic Area Summary GlobalData's "The Biopharmaceutical Industry in 2017: Highlights by Therapeutic Area", provides an insight-rich overview of the key events and trends that shaped the industry during 2017. Within each of the major therapeutic areas covered, GlobalData's analysts have identified the most impactful happenings during 2017 - such as product launches and label expansions, losses of patent protection and market exclusivity, and key clinical trial data readouts - and provided expert insight on the implications of each event. For the biopharmaceutical industry, 2017 was marked by noteworthy innovation as well as disappointments across therapy areas, set against a backdrop of remarkable advances in technology in he......
$275

Italy Tissue Engineered – Skin Substitute Procedures Outlook to 2024

Italy Tissue Engineered - Skin Substitute Procedures Outlook to 2024 Summary GlobalData's new report, Italy Tissue Engineered - Skin Substitute Procedures Outlook to 2024, provides key procedures data on the Italy Tissue Engineered - Skin Substitute Procedures. The report provides procedure volumes within market segments - Biologic Skin Substitute Procedures, Synthetic Skin Substitute Procedures and Biosynthetic Skin Substitute Procedures. The data in the report is derived from dynamic market forecast models. GlobalData uses epidemiology based models to estimate and forecast the procedure volumes. The objective is to provide information that represents the most up-to-date data of the industry possible. The epidemiology-based forecasting model makes use of epidemiology data gath......
$2995

North America Tissue Engineered – Skin Substitute Procedures Outlook to 2024

North America Tissue Engineered - Skin Substitute Procedures Outlook to 2024 Summary GlobalData's new report, North America Tissue Engineered - Skin Substitute Procedures Outlook to 2024, provides key procedures data on the North America Tissue Engineered - Skin Substitute Procedures. The report provides procedure volumes within market segments - Biologic Skin Substitute Procedures, Synthetic Skin Substitute Procedures and Biosynthetic Skin Substitute Procedures. The data in the report is derived from dynamic market forecast models. GlobalData uses epidemiology based models to estimate and forecast the procedure volumes. The objective is to provide information that represents the most up-to-date data of the industry possible. The epidemiology-based forecasting model makes use o......
$3995

Spain Tissue Engineered – Skin Substitute Procedures Outlook to 2024

Spain Tissue Engineered - Skin Substitute Procedures Outlook to 2024 Summary GlobalData's new report, Spain Tissue Engineered - Skin Substitute Procedures Outlook to 2024, provides key procedures data on the Spain Tissue Engineered - Skin Substitute Procedures. The report provides procedure volumes within market segments - Biologic Skin Substitute Procedures, Synthetic Skin Substitute Procedures and Biosynthetic Skin Substitute Procedures. The data in the report is derived from dynamic market forecast models. GlobalData uses epidemiology based models to estimate and forecast the procedure volumes. The objective is to provide information that represents the most up-to-date data of the industry possible. The epidemiology-based forecasting model makes use of epidemiology data gath......
$2995

EU5 Tissue Engineered – Skin Substitute Procedures Outlook to 2024

EU5 Tissue Engineered - Skin Substitute Procedures Outlook to 2024 Summary GlobalData's new report, EU5 Tissue Engineered - Skin Substitute Procedures Outlook to 2024, provides key procedures data on the EU5 Tissue Engineered - Skin Substitute Procedures. The report provides procedure volumes within market segments - Biologic Skin Substitute Procedures, Synthetic Skin Substitute Procedures and Biosynthetic Skin Substitute Procedures. The data in the report is derived from dynamic market forecast models. GlobalData uses epidemiology based models to estimate and forecast the procedure volumes. The objective is to provide information that represents the most up-to-date data of the industry possible. The epidemiology-based forecasting model makes use of epidemiology data gathered f......
$3995
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy